FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.
What happened
FDA inspected Advanced Pharmaceutical Technology's drug manufacturing facility in Elmsford, NY, from July 10 to August 1, 2024. FDA found failures in sterility assurance, slow-release drug testing, process validation, and quality-group oversight of contract labs and manufacturing. The letter also says products listed as export only are new drugs that need FDA approval before U.S. distribution, and that a contract manufacturer was placed on Import Alert 66-79 after failing to provide requested records.
What FDA found
The firm did not have adequate written procedures to prevent microbial contamination and did not monitor the microbial load before sterilization or manufacturing area conditions for products it says are sterile.
21 CFR 211.113(b)The firm did not adequately test products designed to release drug slowly to show each active ingredient releases at the required rate.
21 CFR 211.167(c)The firm increased commercial batch size and released product without adequate process validation, and batch records lacked critical process parameters.
21 CFR 211.100(a)The internal quality group did not adequately oversee a contract testing lab or a contract manufacturer, including test-method validation, release testing, and receipt of a sterile drug without evaluation.
21 CFR 211.22(a)The firm listed products as export only but planned to sell them in the United States as new drugs without FDA approval.
FD&C Act sections 201(p), 505, and 301(d)A contract manufacturer did not respond to FDA requests for records, and FDA placed all drugs from that facility on Import Alert 66-79, an FDA list that can stop U.S. entry of its drugs.
FD&C Act section 704(a)(4) and section 301(e)
What FDA wants
FDA asks the company to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. If it cannot complete corrections in that time, it must state why and give a completion schedule; FDA also recommends a qualified current good manufacturing practice (CGMP) consultant.
Who should pay attention
- companies that buy sterile drugs or drug-device combination products from this firm
- contract manufacturers and testing labs used by drug firms
- outsourcing facilities and their customers
This is a summary. Read the original letter on fda.gov.